|

Revlimid (lenalidomide) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)1

Indications

  • Burkitt Lymphoma1
  • Non-hodgkin Lymphoma1
  • Diffuse Large B-Cell Lymphoma1
  • Lymphoma1
  • Cancer1

Bethesda, Maryland1 trial

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

National Institutes of Health Clinical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.